ClinicalTrials.gg
CompletedNCT00103506Updated Oct 19, 2015Results posted

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

A Phase 3 interventional study of Bortezomib (VELCADE) and Bortezomib (VELCADE) in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 109 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-19.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
646
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 45 studies testing doxorubicin in Multiple Myeloma — none open to participants now, 2 under way, none of them phase 3. Doxorubicin · Multiple Myeloma.

Enrollment
2nd of 42
646 · median 40
Started
2004
with 6 others
Phase 3
6 of 45
none open now
Registered
10th of 45
by date

Among the 45 studies testing doxorubicin in Multiple Myeloma, this one is the 2nd largest by enrollment of the 42 interventional ones that give a count, is one of 7 that started in 2004, is one of 6 in phase 3, and was the 10th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

None of the 45 studies testing doxorubicin in Multiple Myeloma is open now. The open studies under Multiple Myeloma, anywhere →

About doxorubicin

Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 45 studies testing doxorubicin in Multiple Myeloma as a file.
02

Study summary

The purpose of this study is to evaluate time to progression, overall survival, response rate and safety for the two open-label treatment groups; DOXIL/CAELYX in combination with VELCADE vs. VELCADE monotherapy.

Read the detailed description

This is a randomized (study drug assigned by chance), parallel-group, open-label (all involved people know the identity of the intervention), multicenter study in 18 countries. A total of 646 patients with multiple myeloma whose disease has progressed after an initial response to at least 1 line of prior therapy or was refractory to initial treatment will be enrolled. The primary endpoint is time to progression (the interval between the date of randomization and the date of disease progression); secondary endpoints are overall survival (the interval between the date of randomization and the patient's death from any cause), response rate (the proportion of patients in the evaluable population who achieved a complete or partial response), and safety. Other study endpoints include patient reported outcomes and exploratory pharmacogenics (to identify genetic markers of response). Patients are assessed for efficacy and safety every 3 weeks until disease progression is documented or for up to 42 weeks from the start of the first dose of study drug. Patients, who do not progress after the 42-week period, are assessed every 6 weeks until disease progression is documented. Efficacy evaluations includes: serum protein electrophoresis, 24-hour urine collection for protein electrophoresis, skeletal survey (plain films), bone marrow biopsy and aspirate, clinical or radiologic assessment of plasmacytomas, and serum calcium. Responses and progressions are assessed objectively by a computer algorithm based on the EBMT criteria. Safety evaluations include adverse event reports, changes in clinical laboratory findings, and tests for cardiac function (multiple gated acquisition scan/echocardiogram and electrocardiogram). Group A: VELCADE monotherapy: VELCADE 1.3 milligram per meter square (mg/m\^2) to be administered by i.v. bolus on Days 1, 4, 8, and 11 of each 21-day cycle. Group B: DOXIL/VELCADE combination: treated with VELCADE at the same dose and schedule as specified in Group A. DOXIL/CAELYX 30 mg/m\^2 by intravenous infusion given on Day 4 of every 21-day cycle following the administration of VELCADE.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Doxil
  • Caelyx
  • Doxorubicin
  • Velcade
  • Bortezomib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with multiple myeloma who have received at least 1 prior therapy and who have either responded and later had progressive disease or have progressed during their first therapy (primary ) are eligible for the study
  • Patients who may have received prior doxorubicin but not more than a cumulative dose of 240 milligram per meter square (mg/m\^2) doxorubicin, DOXIL, or the equivalent amount of another anthracycline (i.e., 1 mg doxorubicin = 1 mg DOXIL/CAELYX = 1.8 mg epirubicin = 0.3 mg mitoxantrone = 0.25 mg idarubicin)
  • Must have normal cardiac function, as evidenced by a left within institutional normal limits.

Exclusion criteria

Exclusion Criteria:

  • History of treatment with VELCADE or progressive disease while receiving an anthracycline-containing regimen
  • No change in disease status during initial therapy
  • No treatment for within past 5 yrs (other than multiple myeloma) or progressive disease while receiving anthracycline-containing regimen
  • Non-secretory disease
  • Myocardial infarct within past 6 months
  • No major surgery in past 30 days.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
646 participants (actual)

Study arms

  • Active comparator
    VELCADE (bortezomib) monotherapy

    Bortezomib (VELCADE) 1.3 milligram per meter square (mg/m\^2) by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.

    Drug: Bortezomib (VELCADE)

  • Experimental
    DOXIL/CAELYX in combination with VELCADE (bortezomib)

    Bortezomib (VELCADE) 1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.

    Drug: Bortezomib (VELCADE) · Drug: Doxorubicin hydrochloride (DOXIL/CAELYX)

Interventions

  • 1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.

  • 1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles..

  • DrugDoxorubicin hydrochloride (DOXIL/CAELYX)

    Drug page: Doxorubicin

    mg/m\^2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.

06

What researchers measure

Primary outcomes

  1. Time to Progression (TTP)

    Median time to progression of disease is assessed according to International Myeloma Working Group (IMWG) criteria or death from any cause. IMWG criteria: increase of \>=25% from lowest level in Serum M-component or (the absolute increase must be \>=0.5 gram per deciliter \[g/dL\]); Urine M component or (the absolute increase must be \>=200 milligram per 24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase \>10 mg/dL. Bone marrow plasma cell percentage \>=10%. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing. Development of hypercalcemia. Participants who died or dropped out due to any reason without progression will be censored with the day of death or drop-out, respectively and who are alive at the end of the study without any progression was censored with the last available date.

    Time frame: Up to 1 year and 4 months (From date of first participant randomization [20 December 2004] up to interim analysis cut-off date [28 April 2006])

Secondary outcomes

  1. Overall Survival

    The OS is defined as the time from the date of first dose of study drug to date of death from any cause. If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant will be last known to be alive.

    Time frame: Up to 9 years and 5 months (From date of first participant randomization [20 December 2004] to cut-off date for final survival analysis (16 May 2014)

  2. Number of Participants With Serious Adverse Events (SAEs)

    A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Up to 1 year and 11 months (From date of first participant randomization [20 December 2004] to cut-off date for safety update (28 November 2006)

07

Results

Posted May 25, 2015
Limitations and caveats
Study stopped in terms of primary endpoint based on its results at planned interim analysis (28 Apr 2006). However, Long-term follow-up for survival continued until 16 May 2014.

Participant flow

Participant flow — Overall Study
MilestoneVelcade (Bortezomib) MonotherapyDoxil/Caelyx Plus Velcade (Bortezomib)
Started322324
Completed00
Not completed322324
Withdrew: Study closed by sponsor3437
Withdrew: Death257253
Withdrew: Lost to follow-up1313
Withdrew: Withdrawal by subject1821

Outcome measures

PrimaryTime to Progression (TTP)

Median time to progression of disease is assessed according to International Myeloma Working Group (IMWG) criteria or death from any cause. IMWG criteria: increase of \>=25% from lowest level in Serum M-component or (the absolute increase must be \>=0.5 gram per deciliter \[g/dL\]); Urine M component or (the absolute increase must be \>=200 milligram per 24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase \>10 mg/dL. Bone marrow plasma cell percentage \>=10%. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing. Development of hypercalcemia. Participants who died or dropped out due to any reason without progression will be censored with the day of death or drop-out, respectively and who are alive at the end of the study without any progression was censored with the last available date.

Time frame:
Up to 1 year and 4 months (From date of first participant randomization [20 December 2004] up to interim analysis cut-off date [28 April 2006])
Reported as:
Median · Months
Time to Progression (TTP)
MonthsVelcade (Bortezomib) MonotherapyDoxil/Caelyx Plus Velcade (Bortezomib)
Time to Progression (TTP)6.5 (5.6 to 7.1)9.3 (8.2 to 11.1)
SecondaryOverall Survival

The OS is defined as the time from the date of first dose of study drug to date of death from any cause. If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant will be last known to be alive.

Time frame:
Up to 9 years and 5 months (From date of first participant randomization [20 December 2004] to cut-off date for final survival analysis (16 May 2014)
Reported as:
Median · months
Overall Survival
monthsVelcade (Bortezomib) MonotherapyDoxil/Caelyx Plus Velcade (Bortezomib)
Overall Survival30.8 (25.2 to 36.5)33.0 (28.9 to 37.1)
SecondaryNumber of Participants With Serious Adverse Events (SAEs)

A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Up to 1 year and 11 months (From date of first participant randomization [20 December 2004] to cut-off date for safety update (28 November 2006)
Reported as:
Number · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsVelcade (Bortezomib) MonotherapyDoxil/Caelyx Plus Velcade (Bortezomib)
Number of Participants With Serious Adverse Events (SAEs)105120

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Velcade (Bortezomib) Monotherapy—105/318 (33%)299/318 (94%)
Doxil/Caelyx Plus Velcade (Bortezomib)—120/318 (37.7%)313/318 (98.4%)
Most frequent serious events
Showing 10 of 204
Most frequent serious events
EventVelcade (Bortezomib) MonotherapyDoxil/Caelyx Plus Velcade (Bortezomib)
PneumoniaInfections and infestations20/31816/318
PyrexiaGeneral disorders8/31815/318
VomitingGastrointestinal disorders2/31813/318
ThrombocytopeniaBlood and lymphatic system disorders0/3189/318
DiarrhoeaGastrointestinal disorders6/3187/318
NauseaGastrointestinal disorders3/3187/318
DehydrationMetabolism and nutrition disorders6/3186/318
DyspnoeaRespiratory, thoracic and mediastinal disorders6/3182/318
Febrile NeutropeniaBlood and lymphatic system disorders2/3185/318
Herpes ZosterInfections and infestations3/3185/318
Most frequent other events
Showing 10 of 58
Most frequent other events
EventVelcade (Bortezomib) MonotherapyDoxil/Caelyx Plus Velcade (Bortezomib)
NauseaGastrointestinal disorders125/318152/318
DiarrhoeaGastrointestinal disorders122/318142/318
FatigueGeneral disorders88/318115/318
NeutropeniaBlood and lymphatic system disorders71/318113/318
ThrombocytopeniaBlood and lymphatic system disorders89/318104/318
ConstipationGastrointestinal disorders98/31899/318
VomitingGastrointestinal disorders67/31893/318
PyrexiaGeneral disorders67/31891/318
AnaemiaBlood and lymphatic system disorders67/31880/318
AstheniaGeneral disorders56/31870/318

Baseline characteristics

Age, Continuous
Age, Continuous(years)Velcade (Bortezomib) MonotherapyDoxil/Caelyx Plus Velcade (Bortezomib)Total
Mean61.5 ± 9.5661.4 ± 9.6161.4 ± 9.58
Sex: Female, Male
Sex: Female, Male(Participants)Velcade (Bortezomib) MonotherapyDoxil/Caelyx Plus Velcade (Bortezomib)Total
Female148135283
Male174189363
Region of Enrollment
Region of Enrollment(participants)Velcade (Bortezomib) MonotherapyDoxil/Caelyx Plus Velcade (Bortezomib)Total
ARGENTINA6915
AUSTRALIA313162
AUSTRIA12618
BELGIUM-LUXEMBURG61420
CANADA202343
CZECH REPUBLIC142236
FRANCE212849
GREAT BRITAIN8715
ISRAEL252146
ITALY171128
NETHERLANDS293261
POLAND351752
PORTUGAL61420
RUSSIA383472
SINGAPORE325
SOUTH AFRICA131528
SPAIN201535
UNITED STATES OF AMERICA182341
08

Study locations

109 sites
  • Alabaster, Alabama, United States
  • Surprise, Arizona, United States
  • Berkeley, California, United States
  • Loma Linda, California, United States
  • Los Angeles, California, United States
  • Sacramento, California, United States
  • Norwalk, Connecticut, United States
  • Stamford, Connecticut, United States
  • Jacksonville, Florida, United States
  • Miami, Florida, United States
  • Stuart, Florida, United States
  • West Palm Beach, Florida, United States
  • Altanta, Georgia, United States
  • Boise, Idaho, United States
  • Indianapolis, Indiana, United States
  • Lexington, Kentucky, United States
  • Metairie, Louisiana, United States
  • New Orleans, Louisiana, United States
  • Minneapolis, Minnesota, United States
  • Hackensack, New Jersey, United States
  • Chapel Hill, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Durham, North Carolina, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • N Charleston, South Carolina, United States
  • Nashville, Tennessee, United States
  • Buenos Aires, Argentina
  • Ciudad De Buenos Aires, Argentina
  • La Plata, Argentina
  • Mendoza, Argentina
  • Adelaide, Australia
  • Darlinghurst, Australia
  • Melbourne, Australia
  • Perth, Australia
  • Sydney, Australia
  • Graz, Austria
  • Innsbruck, Austria
  • Salzburg, Austria
  • Wels N/A, Austria
  • Wien, Austria
  • Brussel, Belgium
  • Gent, Belgium
  • Leuven, Belgium
  • Mont-Godinne, Belgium
  • Vancouver, British Columbia, Canada
  • Hamilton, Ontario, Canada
  • Ottawa, Ontario, Canada
  • Montreal, Quebec, Canada
  • N/a N/a, Canada
  • Quebec, Canada
  • Brno, Czech Republic
  • Olomouc, Czech Republic
  • Praha 2 N/A, Czech Republic
  • Angers Cedex 1 N/A, France
  • Bobigny, France
  • Creteil N/A, France
  • Lille Cedex N/A, France
  • Nantes N/A, France
  • Pierre Benite, France
  • Toulouse, France
  • Tours, France
  • Vandoeuvre Les Nancy, France
  • Haifa, Israel
  • Jerusalem, Israel
  • Petach Tikva, Israel
  • Ramat Gan, Israel
  • Rehovot, Israel
  • Tel Aviv, Israel
  • Amersfoort, Netherlands
  • Amsterdam Zuidoost, Netherlands
  • Amsterdam, Netherlands
  • Delft, Netherlands
  • Den Haag, Netherlands
  • Groningen, Netherlands
  • Nieuwegein, Netherlands
  • Nijmegen, Netherlands
  • Rotterdam, Netherlands
  • Utrecht, Netherlands
  • Bialystok, Poland
  • Gdansk, Poland
  • Lodz, Poland
  • Lublin, Poland
  • Warszawa, Poland
  • Wroclaw, Poland
  • Coimbra, Portugal
  • Lisboa, Portugal
  • Porto N/A, Portugal
  • Arkhangelsk, Russian Federation
  • Ekaterinburg, Russian Federation
  • Izhevsk, Russian Federation
  • Moscow N/A, Russian Federation
  • Moscow, Russian Federation
  • Nizhny Novgorod, Russian Federation
  • Novosibirsk, Russian Federation
  • Obninsk, Russian Federation
  • St. Petersburg, Russian Federation
  • Singapore, Singapore
  • Bloemfontein N/A, South Africa

Showing the first 100 of 109 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Dimopoulos MA, Orlowski RZ, Facon T, Sonneveld P, Anderson KC, Beksac M, Benboubker L, Roddie H, Potamianou A, Couturier C, Feng H, Ataman O, van de Velde H, Richardson PG. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica. 2015 Jan;100(1):100-6. doi: 10.3324/haematol.2014.112037. Epub 2014 Sep 26. PubMed 25261096 ↗
  • Sonneveld P, Hajek R, Nagler A, Spencer A, Blade J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ; DOXIL-MMY-3001 Study Investigators. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer. 2008 Apr 1;112(7):1529-37. doi: 10.1002/cncr.23326. PubMed 18300257 ↗
  • Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007 Sep 1;25(25):3892-901. doi: 10.1200/JCO.2006.10.5460. Epub 2007 Aug 6. PubMed 17679727 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of May 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in May 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2005
First posted
Feb 10, 2005
Start
Dec 2004
Primary completionActual
May 2014
CompletionActual
Jun 2014
Results first posted
May 25, 2015
Last update
Oct 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00103506
Responsible party
Sponsor
First posted
Feb 10, 2005
Start date
Dec 2004
Primary completion
May 2014
Completion
Jun 2014
Results posted
May 25, 2015
Last update
Oct 19, 2015

Study contacts

Janssen Research & Development, LLC C. Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxorubicin

Start the discussion